Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells

被引：0
作者：
Haijun Zhao
Yuelong Jiang
Fusheng Lin
Mengya Zhong
Jinshui Tan
Yong Zhou
Long Liu
Guowei Li
Manman Deng
Bing Xu
机构：
[1] The First Affiliated Hospital of Xiamen University and Institute of Hematology,Department of Hematology
[2] School of Medicine,Department of Hematology
[3] Xiamen University,undefined
[4] Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy,undefined
[5] Huizhou Municipal Central Hospital,undefined
来源：
Experimental Hematology & Oncology | / 11卷
关键词：
Leukemia stem and progenitor cells; Acute myeloid leukemia (AML); Apatinib; Chidamide; VEGFR; Bcl2; Patient-derived xenografts;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 208 条
  • [1] Dohner H(2015)Acute myeloid leukemia N Engl J Med 373 1136-1152
  • [2] Weisdorf DJ(2017)Therapeutic targeting of acute myeloid leukemia stem cells Blood 129 1627-1635
  • [3] Bloomfield CD(2017)Biology and relevance of human acute myeloid leukemia stem cells Blood 129 1577-1585
  • [4] Pollyea DA(2019)Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia Blood 133 7-17
  • [5] Jordan CT(2018)Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia Nat Med 24 1859-1866
  • [6] Thomas D(2020)Azacitidine and venetoclax in previously untreated acute myeloid leukemia N Engl J Med 383 617-629
  • [7] Majeti R(2020)Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells Nat Cancer 1 1176-1187
  • [8] DiNardo CD(2021)Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia Cancer Drug Resist 4 125-142
  • [9] Pratz K(2018)Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi Front Oncol 8 92-34
  • [10] Pullarkat V(2015)Altered expression of histone deacetylases in cancer Crit Rev Oncog 20 19-611
12345678910